Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
L-Glutamine (Endari)
Treatment for Sickle cell disorders
Typical Dosage: 10-30 g daily, based on weight
Effectiveness
55%
Safety Score
85%
Clinical Trials
7
Participants
400
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
10-30 g daily, based on weight
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$35,000
Monitoring:$200
Side Effect Mgmt:$100
Total Annual:$35,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$400,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$141,200
L-Glutamine (Endari) Outcomes
for Sickle cell disorders
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+25%
Common Side Effects
Nausea
+8%
Headache
+7%
Abdominal pain
+5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
5 completed trials for L-Glutamine (Endari) in Sickle cell disorders
Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
NCT04684381COMPLETEDPHASE4
13 participants
INTERVENTIONAL
Cincinnati, United States
Started: Jan 4, 2021
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
NCT00125788COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Bellflower, United States +4 more
Started: Mar 1, 2004
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
NCT01179217COMPLETEDPHASE3
230 participants
INTERVENTIONAL
Mobile, United States +30 more
Started: May 1, 2010
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
NCT01048905COMPLETEDPHASE2
13 participants
INTERVENTIONAL
Oakland, United States
Started: Mar 1, 2009
Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients
NCT05371184COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Cairo, Egypt +1 more
Started: Jan 4, 2022